Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market
SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Altruist Biologics, a world-class contract development and manufacturing organization (CDMO) and wholly owned subsidiary of Innovent Biologics (1801.HK), announced that its Suzhou commercial manufacturing facility has successfully passed a...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Gateway Business Health Coalition Partners with Rezilient Health to Bring Tech-Enabled, More Affordable Primary Care to Its Members
- Chronic Pain Market Poised for Growth at a CAGR of 5% During the Forecast Period (2026-2036), as Rising Patient Burden and Novel Treatment Approaches are Creating New Opportunities | DelveInsight
- CellsBin® Closes Series A Financing Led by 108 BioCapital to Advance Its Rare-Cell Intelligence™ Platform
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →